

## Datasheet: HCA255

<b>Description:</b>	HUMAN ANTI TOCILIZUMAB
<b>Specificity:</b>	TOCILIZUMAB
<b>Other names:</b>	ACTEMRA®, ROACTEMRA®
<b>Format:</b>	Purified
<b>Product Type:</b>	Monoclonal Antibody
<b>Clone:</b>	AbD21346_hIgG1
<b>Isotype:</b>	IgG1
<b>Quantity:</b>	0.1 mg

## Product Details

### Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit [www.bio-rad-antibodies.com/protocols](http://www.bio-rad-antibodies.com/protocols).

	Yes	No	Not Determined	Suggested Dilution
ELISA	■			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

### Product Form

Human IgG1 antibody (kappa light chain) selected from the HuCAL® phage display library and expressed in a human cell line. This antibody is supplied as a liquid.

### Preparation

Purified IgG prepared by affinity chromatography on Protein A

### Buffer Solution

Phosphate buffered saline

### Preservative Stabilisers

0.01% Thiomersal

### Approx. Protein Concentrations

Antibody concentration 0.5 mg/ml

### Immunogen

Tocilizumab

### Specificity

**Human Anti-Tocilizumab Antibody, clone AbD21346\_hIgG1** is a paratope specific, anti-idiotypic antibody that binds to free tocilizumab but not to human Interleukin-6 Receptor (IL-6R) or the drug/IL-6R complex.

Clone AbD21346\_hIgG1 is a fully human recombinant monoclonal antibody with IgG1 isotype and is suitable as a surrogate positive control or calibrator (medium affinity) in an anti-drug antibody (ADA) assay.

Tocilizumab (RoActemra/Actemra) is a humanized IgG1/kappa monoclonal antibody approved for the treatment of moderate to severe rheumatoid arthritis and for the treatment of systemic juvenile idiopathic arthritis. The therapeutic antibody is directed against IL-6R and acts by blocking the binding of IL-6R (both the soluble form, sIL-6R, and the membrane bound form, mIL-6R) to IL-6, thus impeding the pro-inflammatory properties of this cytokine.

[View a summary of all anti-tocilizumab antibodies](#)

---

<b>Affinity</b>	The monovalent intrinsic affinity of this antibody was measured as $K_D=6.2$ nM by real time, label-free molecular interaction analysis on immobilized tocilizumab.
<b>ELISA</b>	This product may be used in a direct ELISA or as a detection reagent in a bridging ELISA together with <a href="#">HCA252</a> as the capture reagent. Protocol: <a href="#">PK bridging ELISA to measure free drug</a> This antibody is fully human and can be used as a reference standard in an ADA assay. Protocol: <a href="#">ADA bridging ELISA</a>
<b>Storage</b>	Store at +4°C or at -20°C if preferred. Storage in frost-free freezers is not recommended. This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use
<b>Guarantee</b>	12 months from date of despatch
<b>Acknowledgements</b>	Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany. Actemra® and RoActemra® are registered trademarks of Hoffman-La Roche and Chugai Pharmaceuticals co., Ltd.
<b>Health And Safety Information</b>	Material Safety Datasheet documentation #10094 available at: 10094: <a href="https://www.bio-rad-antibodies.com/uploads/MSDS/10094.pdf">https://www.bio-rad-antibodies.com/uploads/MSDS/10094.pdf</a>
<b>Licensed Use</b>	For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
<b>Regulatory</b>	For research purposes only
<b>Technical Advice</b>	Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the <a href="#">HuCAL Antibodies Technical Manual</a>

---

## Related Products

### Recommended Useful Reagents

[HUMAN ANTI TOCILIZUMAB \(HCA252\)](#)

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK001P\)](#)

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK002P\)](#)

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK003P\)](#)

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK004P\)](#)

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK005P\)](#)

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK006P\)](#)

[HUMAN ANTI TOCILIZUMAB \(HCA253\)](#)

[HUMAN ANTI TOCILIZUMAB \(HCA254\)](#)

[HUMAN ANTI TOCILIZUMAB \(HCA256\)](#)

[HUMAN ANTI TOCILIZUMAB \(HCA257\)](#)

**North & South America** Tel: +1 800 265 7376  
Fax: +1 919 878 3751  
Email: [antibody\\_sales\\_us@bio-rad.com](mailto:antibody_sales_us@bio-rad.com)

**Worldwide** Tel: +44 (0)1865 852 700  
Fax: +44 (0)1865 852 739  
Email: [antibody\\_sales\\_uk@bio-rad.com](mailto:antibody_sales_uk@bio-rad.com)

**Europe** Tel: +49 (0) 89 8090 95 21  
Fax: +49 (0) 89 8090 95 50  
Email: [antibody\\_sales\\_de@bio-rad.com](mailto:antibody_sales_de@bio-rad.com)

'M371686:200612'

**Printed on 11 Aug 2020**

---

© 2020 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)